# INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

> **NCT03491683** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Inovio Pharmaceuticals** · enrollment: 52 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **BIOLOGICAL:** INO-5401
- **BIOLOGICAL:** INO-9012
- **BIOLOGICAL:** Cemiplimab
- **RADIATION:** Radiation Therapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT03491683
- **Lead sponsor:** Inovio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-31
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03491683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03491683, "INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03491683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*